key: cord-0928168-c1cl4ptu authors: Nishijima, Yoshinori; Hader, Shelby N; Hanson, Alena J; Zhang, David X; Sparapani, Rodney; Gutterman, David D; Beyer, Andreas M title: Prolonged endothelial-dysfunction in human arterioles following infection with SARS-CoV-2 date: 2021-11-10 journal: Cardiovasc Res DOI: 10.1093/cvr/cvab339 sha: bff5cffd95d195d4963c80033d22882ada07b64b doc_id: 928168 cord_uid: c1cl4ptu nan Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has a major global impact and is responsible for over 230 million cases and 4.7 million deaths worldwide. 1 More than 200 different chronic symptoms have been identified to occur following recovery from the virus. 2 Impaired endothelial function, especially in the microcirculation plays a crucial role in regulating tissue perfusion and is strongly predictive of future cardiovascular adverse events. 3 In conduit arteries, impaired flow-mediated dilation (FMD) persists in COVID-19 patients for 3-4 weeks after a positive SARS-CoV-2 test compared with healthy controls. 4 However, the effects of SARS-CoV-2 infection in resistance microvessels remain unknown. The present study aimed to evaluate the magnitude and duration of microvascularendothelial-(dys) function post-infection with SARS-CoV-2. Discard surgical specimens were collected (no consent necessary) as approved by Institutional Review Board of the Medical College of Wisconsin and in accordance with the Declaration of Helsinki. Fresh human microvessels (average internal-diameter 152 ± 7 mm) were isolated from adipose or atrial appendages. All patients tested negative for SARS-CoV-2 prior to surgery. To avoid undetected prior COVID-19 infection, historic data pre-October 2019 were used, classified for cardiovascular risk factors (RF) as previously published 5 and grouped as historic-controls (n = 19, 2 males/17 females, 44 ± 3 years, 14 white/5 non-white, risk-score 0.2 ± 0.1); historic-control with similar in cardiovascular RF (Historic-CTRLþSimilar RF; n = 28, 5 males/23 females, 42± 1 years, 20 white/8 non-white, coronary artery disease (CAD) 4, hypertension 7, hyperlipidaemia 8, diabetes mellitus 1, > _60 years 0, risk-score 3.8 ± 0.6); controls with more severe cardiovascular RFs (historic-CTRLþRFþþ; n = 13, 10 males/3 females, 64 ± 2 years, 10 white/3 non-white, CAD 10, hypertension 9, hyperlipidaemia 8, diabetes mellitus 7, age > _60 years 8, risk-score 6.4 ± 0.7) and compared to patients with prior SARS-CoV-2 positive test (p-SARS-CoV-2þ; n = 26, 3 males/23 females, 48 ± 3 years, 14 white/12 non-white, CAD 2, hypertension 13, hyperlipidaemia 9, diabetes mellitus 9, age > _60 years 7, risk-score 3.2 ± 0.7). Among p-SARS-CoV-2þ subjects, the time between positive and negative PCR test results was stratified to < _3 months (n = 9), or 4-16 months (n = 17). Microvascular dilation was assessed in vitro using videomicroscopy as previously described. 6 Data are presented as %Maximal dilation at given dose ± SEM. Statistical analysis was performed for %Maximal dilation by 2-way-ANOVA vs. pressure gradient (cmH 2 O, Figure 1A ) and one-way-ANOVA with multiple comparisons accounting for time since SARS-CoV-2þ (months, Figure 1B ). Endothelial-dependent dilation to acetylcholine (at 10 -5 M, p-SARS-CoV-2þ: 71 ± 4%*, n = 9 vs. historic-CTRL: 95 ± 3%, n = 16, *P < 0.05), and FMD (at 100 cmH 2 O, p-SARS-CoV-2þ: 46 ± 3%*, n = 26 vs. historic CTRL: 86 ± 2%, n = 6, Historic-CTRLþSimilar RF: 88 ± 2%, n = 28, and Historic-CTRLþRFþþ: 86 ± 2%, n = 13, *P < 0.05, Figure 1A) were markedly reduced in p-SARS-CoV-2þ subjects. Smooth-muscle mediated, endothelial-independent dilation to sodium nitroprusside (at 10 -4 M, p-SARS-CoV-2þ: 84 ± 6% vs. historic-CTRL: 92 ± 2%, n = 5/group) was not altered by SARS-CoV-2 exposure. Stratification by time since p-SARS-CoV-2þ, patient age, and race revealed no impact of age or racial/ethnic background on endothelial function. Reduced endothelial dilator capacity persisted several months after SARS-CoV-2 exposure ( Figure 1B) . Our findings indicate endothelial-dependent dilation in human arterioles is impaired for months after SARS-CoV-2 exposure. This finding might contribute to long-lasting symptoms of post-COVID-19 infection and could directly increase risks for future cardiovascular events. The degree of endothelial dysfunction is inversely related to time after SARS-CoV-2 infection. Further studies are needed to confirm these findings and define the impact of disease progression/severity, biological predisposition, social, and environmental influences on endothelial function following infection with SARS-CoV-2. Data were collected in isolated arterioles from subjects with a variety of cardiovascular RFs that might affect vasodilator responses. However, compared to historical pre-COVID era data, no significant difference between controls and patients with similar risk profile as p-SARS-CoV-2þ patients were observed, suggesting that SARS-CoV2 can incite endothelial dysfunction. Due to the de-identified nature of sample collection, we could not assess the role of systemic changes (e.g. inflammation) or determine if the severity of COVID-19 symptoms or different treatment regimens contribute to the degree of endothelial-dysfunction observed. However, endothelial dysfunction was observed in a subset of patients when the severity of infection was reported (symptomatic: FMD at 100 cmH 2 O, 54 ± 9%, time since SARS-CoV-2 þ 8 -12 months, n = 3 vs. asymptomatic: 38 ± 8%, time since p-SARS-CoV-2þ < _3 months, n = 3), suggesting the phenotype links to the infection itself rather than treatment or severity of the disease. In conclusion, we observed significantly reduced endothelialdependent dilation months after exposure to SARS-CoV-2 that may lead to future cardiovascular complications. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact Coronary endothelial function testing provides superior discrimination compared with standard clinical risk scoring in prediction of cardiovascular events Vascular alterations among young adults with SARS-CoV-2 A novel scoring system to estimate chemotherapy-induced myocardial toxicity: risk assessment prior to non-anthracycline chemotherapy regimens Endothelium-dependent, flow-induced dilation of isolated coronary arterioles Conflict of interest: none declared. This work was supported by the National Institutes of Health [R01HL133029 to A.M.B. and R01HL096647 to D.X.Z].